Ruth Ladenstein

Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Paolo G. Casali, Stefan Bielack, N. Abecassis et al. · Annals of Oncology · 2018 · 618 citations · Full text

Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial

Ruth Ladenstein, Ulrike Pötschger, Marie‐Cécile Le Deley et al. · Journal of Clinical Oncology · 2010 · 528 citations · Full text

Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

Sandra J. Strauss, Anna Maria Frezza, N. Abecassis et al. · Annals of Oncology · 2021 · 408 citations · Full text

Bone Disease, Bone Sarcomas, Surgical Oncology +5

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 379 citations

Interleukin 2, Autoimmune Disease, Anti-gd2 Antibody Ch14.18/cho +7

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 334 citations · Full text

Oncology, Medicine, Versus Carboplatin +8